The purpose of the Administration, Evaluation and Planning Core is to ensure the coordination of the Dana- Farber/Harvard Cancer Center (DF/HCC) Lung Cancer SPORE components and to provide oversight and leadership of the scientific, administrative, and fiscal aspects of the SPORE.Within the DF/HCC Lung Cancer SPORE, there are several layers of oversight and evaluation. Dr. Johnson, as SPORE Director, monitors the progress of the Projects and Cores and oversees the Career Development Program (along with Drs. David Christian! and Daniel Tenen), the Developmental Research Program (along with Dr. David Kwiatkowski), and all other proposed activities. Within the DF/HCC, Dr. Johnson has the authority and resources to ensure the success of this SPORE. Our Governance Committee, made up of senior members of the DF/HCC Lung Cancer Program, meets monthly to provide immediate decision-making. Dr. Johnson will be joined by David Christiani, Professor of Medicine and Public Health, to assume the responsibility as Co-Pi of the SPORE. Dr. Christiani brings his leadership expertise in pulmonary medicine and public health to our proposed studies in lung cancer. We have a strong Internal Advisory Board, comprised o f prominent members of the Harvard Medical School community and representing the participating institutions and major cancer research disciplines. Our External Advisory Board will meet in the Boston area annually during the five-year funding cycle. The membership and functions of these committees are discussed in detail in the description of this Core.The Administration, Evaluation and Planning Core allows for the provision of stimulating intellectual activities, organization of venues for planning future research through seminars and retreats, and the oversight of research and spending. This Core also provides the tools to work with institutions inside and outside of Harvard University to leverage the considerable power of the SPORE in order to raise more research funding for lung cancer. The responsibilities of the Administration, Evaluation and Planning Core are to: 1) Select research projects and evaluate research progress;2) Foster collaborative research within the SPORE and between SPOREs;3) Integrate the Lung SPORE into the DF/HCC structure;4) Provide necessary resources and fiscal oversight and 5) Promote rapid dissemination of significant research findings and facilitate resource exchange.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090578-10
Application #
8377871
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
10
Fiscal Year
2012
Total Cost
$619,944
Indirect Cost
$70,272
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Shea, Meghan; Costa, Daniel B; Rangachari, Deepa (2016) Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis 10:113-29
Kang, Xiaozheng; Liu, Hongliang; Onaitis, Mark W et al. (2016) Polymorphisms of the centrosomal gene (FGFR1OP) and lung cancer risk: a meta-analysis of 14,463 cases and 44,188 controls. Carcinogenesis 37:280-9
Kachuri, Linda; Amos, Christopher I; McKay, James D et al. (2016) Fine mapping of chromosome 5p15.33 based on a targeted deep sequencing and high density genotyping identifies novel lung cancer susceptibility loci. Carcinogenesis 37:96-105
Kinsey, C Matthew; San Jose Estepar, Raul; Van der Velden, Jos et al. (2016) Lower Pectoralis Muscle Area is Associated with a Worse Overall Survival in Non- Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev :
Koyama, Shohei; Akbay, Esra A; Li, Yvonne Y et al. (2016) STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res 76:999-1008
Planchard, David; Besse, Benjamin; Groen, Harry J M et al. (2016) Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17:984-93
Patel, Yesha M; Park, Sunghim L; Han, Younghun et al. (2016) Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk. Cancer Res 76:5768-5776
Nishino, Mizuki; Dahlberg, Suzanne E; Fulton, Linnea E et al. (2016) Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Acad Radiol 23:329-36
Shea, Meghan; Huberman, Mark S; Costa, Daniel B (2016) Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma. J Thorac Oncol 11:e81-2
Sacher, Adrian G; Dahlberg, Suzanne E; Heng, Jennifer et al. (2016) Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. JAMA Oncol 2:313-20

Showing the most recent 10 out of 241 publications